Clinical trials: Influenza (Pandemic)
Influenza
H5N1 Vaccine Intramuscular Versus Intradermal in Healthy Adults
The purpose of this research study is to compare how the body reacts to different strengths of an H5N1 flu vaccine when given by different routes of injection (injection into the skin or into the muscle).
- Trial name
- NCT00310206
- Testing
- Inactivated Influenza A Vaccine A/H5N1
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
A/H1N1 Influenza, Swine Flu
Case-control Study of Pandemic A/H1N1 Influenza Risk Factors In Lebanon
The pandemic A/H1N1 virus was named "swine flu" when the current outbreak started. Although it is not yet confirmed that the index case acquired the virus from pigs, the nomenclature "swine flu" was due to the fact that the virus…
- Trial name
- NCT01298206
- Where
- Lebanon
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- St. Jude Children's Research Hospital
Influenza, Healthy
Study of a Parenterally Administered H5N1 Influenza Vaccine in Healthy Adults
The safety and tolerability of the pandemic A/H5N1 virosomal vaccine formulated with or without the 3rd generation ISCOM™ adjuvant for parenteral administration will be investigated locally and systemically and by using…
- Trial name
- PANFLUVAC (NCT00868218)
- Testing
- Influenza vaccine
- Where
- Norway
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Rebecca Cox
Upper Respiratory Tract Infection, Influenza
A Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As First Line Treatment For Human Swine Influenza Infection
To evaluate the efficacy of oseltamivir ,as compared with the placebo arm and zanamivir with its control arm with respect to symptoms duration among patients infected with influenza A (H1N1) virus.
- Trial name
- NCT00979667
- Testing
- Oseltamivir, Zanamivir
- Where
- 3 sites in China, Hong Kong
- Volunteers
- 4 people
- Sponsor
- Chinese University of Hong Kong
Pandemic, Avian Influenza
Immunogenicity, Safety and Tolerability of Prepandemic Influenza and Seasonal Influenza Vaccine in Adult Subjects
This study evaluates the immunogenicity, safety and tolerability of an H5N1 vaccine with a seasonal trivalent influenza vaccine, containing the strains recommended by WHO for the 2007 influenza season in the Southern Hemisphere.
- Trial name
- NCT00481065
- Testing
- MF59-eH5N1, eTIV_a, MF59-eH5N1 + eTIV_a
- Where
- Colombia
- Volunteers
- 405 people, healthy volunteers welcome
- Sponsor
- Novartis
Influenza, Pandemic Influenza
A/H1N1 Immunogenicity and Safety in Adults
The purpose of the study is to obtain immunogenicity and safety data at different dose levels of an investigational H1N1 pandemic influenza vaccine in healthy adults 18 years of age and older.
- Trial name
- NCT00959465
- Testing
- H1N1 pandemic influenza vaccine (whole virion, Vero Cell-derived, inactivated)
- Where
- 5 sites in Austria, Germany
- Volunteers
- 408 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Influenza
Project to Investigate Ways to Reduce the Spread of Influenza in Schools and Households With Children
The purpose of this study is to understand the spread of influenza (flu) in schools and households with elementary (K-5) school children, and develop ways to reduce the flu using non-pharmaceutical means.
- Trial name
- PIPP (NCT00446628)
- Testing
- behaviors reducing spread of influenza
- Where
- United States
- Volunteers
- 3,360 people, healthy volunteers welcome
- Sponsor
- Kiren Mitruka
Influenza
Novartis Pandemic Influenza A (H1N1) Vaccine(s) Observational Comparative Safety Study
The primary objective of this observational, comparative safety study is to evaluate the safety of the Novartis Pandemic Influenza A (H1N1) vaccine in pregnant women and their off spring, followed for up to 3 months of age as…
- Trial name
- NCT01037829
- Testing
- Non-intervention observational study
- Where
- 17 sites in Argentina, Italy and 1 more
- Volunteers
- 4,529 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza, Orthomyxoviridae Infections
Study of Different Formulations of an Intramuscular A/H5N1 Inactivated, Split Virion Influenza Adjuvanted Vaccine
Following the licensure of sanofi pasteur's 90 µg rgA/Vietnam/1203/2004 pandemic influenza vaccine, efforts to develop a lower antigen dose formulation with improved immunogenicity using adjuvants were initiated.
- Trial name
- NCT00664417
- Testing
- Monovalent subvirion H5N1 influenza vaccine, Physiological saline
- Where
- 6 sites in United States
- Volunteers
- 375 people, healthy volunteers welcome
- Sponsor
- Sanofi
Influenza
A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults
The purpose of this study is to evaluate humoral immunogenicity after 2 doses of mRNA-1018-H5, and to evaluate the safety and reactogenicity of mRNA-1018-H5 in adults ≥18 years of age.
- Trial name
- NCT07496450
- Testing
- mRNA-1018-H5
- Where
- 35 sites in United States, United Kingdom
- Volunteers
- 4,050 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Influenza
A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults
The purpose of this Phase 1/2 study is to generate sufficient safety and immunogenicity data of mRNA-1018 pandemic influenza candidate vaccines in healthy adults ≥18 years of age to enable the initiation of a large Phase 3 trial…
- Trial name
- NCT05972174
- Testing
- mRNA-1018 for H5N8, mRNA-1018 for H7N9, mRNA-1018 for H5 Only
- Where
- 27 sites in United States, United Kingdom
- Volunteers
- 1,504 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Pandemic Influenza, Prevention
Safety and Immunogenicity of an Inactivated Pandemic Influenza Vaccine
A single center, randomized and double-blind phase II clinical trial is to be conducted in adults to evaluate the safety and immunogenicity of an inactivated pandemic influenza vaccine (whole-virion, aluminium-adjuvanted).
- Trial name
- NCT00535665
- Testing
- pandemic influenza vaccine (H5N1 strain NIBRG-14)
- Volunteers
- 402 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Influenza
Tolerability and Safety Study of FLUVAL P Monovalent Influenza Vaccine in Children
To determine the tolerability and safety of FLUVAL P monovalent influenza vaccine in children.
- Trial name
- NCT01100294
- Testing
- Vaccination with FLUVAL P
- Where
- Hungary
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Fluart Innovative Vaccine Ltd, Hungary
Influenza, Swine-origin A/H1N1 Influenza
A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy Europeans Children Aged 6 to 35 Months
The purpose of this study is to generate data on immunogenicity and safety of the monovalent H1N1 vaccine in support of the development and registration.
- Trial name
- NCT00956046
- Testing
- Swine A/H1N1 influenza vaccine (split virion, inactivated), Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)
- Where
- 15 sites in Finland
- Volunteers
- 401 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Pandemic Influenza, Influenza A Virus Infection
Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults
The purpose of this study is to test different adjuvanted vaccine formulations as a two-dose schedule in immunologically naïve adults against one vaccine formulation without adjuvant in terms of tolerance and immunogenicity…
- Conditions
- Pandemic Influenza, Influenza A Virus Infection, Orthomyxoviridae Infections
- Trial name
- NCT00457509
- Testing
- A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant, A/H5N1 inactivated, split-virion influenza vaccine
- Where
- 3 sites in Belgium
- Volunteers
- 251 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
H1N1 Influenza
Antibody Production Following H1N1 Influenza Vaccination After Stem Cell and Heart Transplantation
Stem cell and and heart transplant patients will receive pandemic H1N1 influenza vaccination according to the clinical guidelines. In these patients the investigators will measure the specific antibody production.
- Trial name
- NCT01008683
- Where
- Israel
- Volunteers
- 300 people
- Sponsor
- Hadassah Medical Organization
Influenza
Study to Evaluate the Safety and Immunogenicity of MG1109 in Healthy Adult Volunteers
This study was designed in two steps with Step 1, a single-center, double-blind, randomized clinical Pilot study and Step 2, a multi-center, single-blind, randomized clinical Pivotal study.
- Trial name
- NCT01389466
- Testing
- Step 1, Step 2
- Where
- 4 sites in South Korea
- Volunteers
- 346 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Influenza
Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Adolescents
A single center, stratified, randomized and double-blind phase II clinical trial was conducted in adolescents to evaluate the safety and immunogenicity of a split-virion pandemic influenza A vaccine (H5N1).
- Trial name
- NCT00900588
- Testing
- split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Influenza Viral Infections, Respiratory Viral Infection
Severe Acute Respiratory Infections (SARI) in Belgium (2011-2020)
The Belgian Severe Acute Respiratory Infections network (BELSARI-net) was implemented during the influenza season 2011-2012 following the recommendations of the World Health Organization (WHO) to monitor severity of influenza…
- Conditions
- Influenza Viral Infections, Respiratory Viral Infection, Severe Acute Respiratory Infection
- Trial name
- SARIpreSC2 (NCT05620953)
- Testing
- respiratory specimen
- Volunteers
- 12,145 people
- Sponsor
- Sciensano
Influenza
Reactogenicity, Safety, and Immunogenicity of a Live Monovalent H5N2 Influenza Vaccine
To evaluate the safety profile of two intranasal doses of LAIV A/17/turkey/Turkey/05/133 (H5N2) in healthy adults.
- Trial name
- NCT01719783
- Testing
- LAIV H5N2
- Where
- Russia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- PATH